ArticlemSphere2026
Cutaneous human papillomavirus E6 impairs the cGAS-STING pathway.
Article in mSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Differential STING and p53 expression in epidermodysplasia verruciformis-associated versus non-EV cutaneous squamous cell carcinomas.Medical oncology (Northwood, London, England) · 2026Article
- The Significance of cGAS-STING Signaling in Response to Oncogenic Viruses.Cell biochemistry and function · 2026Review
- Integrated transcriptomic profiling reveals oncogenic pathways and chimeric transcripts in equine sarcoid lesions with predominant BPV1 detection.Frontiers in molecular biosciences · 2026Article
- Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade.Frontiers in immunology · 2026Review
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Beta human papillomaviruses (β-HPVs) are ubiquitous double-stranded DNA (dsDNA) viruses that may promote skin cancers by destabilizing the host genome. Supporting this, expression of the E6 gene from a β-HPV (β-HPV 8 E6) results in increased micronuclei that should induce an innate immune response that eliminates these cells. However, β-HPV 8 E6 promotes rather than restricts proliferation. We hypothesize that β-HPV 8 E6 accomplishes this by attenuating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, an innate immune pathway that becomes activated in response to cytosolic dsDNA. Here, we show that in response to dsDNA transfection, β-HPV 8 E6 reduced the intensity of cGAS-STING pathway activation via a reduction in STING phosphorylation. Additionally, our unbiased assessment found that β-HPV 8 E6 broadly downregulates innate immunity. This impairment of the cGAS-STING innate immune response could contribute to the prevalence of β-HPV infections.IMPORTANCEBeta human papillomaviruses (β-HPVs) may promote non-melanoma skin cancers in certain immunocompromised populations by destabilizing the host genome. Our group has previously documented the ability of a specific β-HPV, type 8, to promote proliferation despite antiproliferative stimuli, including mitotic errors such as anaphase bridges, micronuclei, and chromothripsis. The mechanisms β-HPV uses to overcome these challenges are not yet fully elucidated. This paper addresses one possible mechanism by proposing that β-HPVs suppress cGAS-STING signaling to promote proliferation under conditions that would typically initiate an innate immune response, resulting in apoptosis or senescence. We found that β-HPVs can impair cGAS-STING signaling at a post-translational modification level and play a role in broadly downregulating innate immune-associated genes. Similarly, alpha human papillomaviruses (α-HPVs) display the ability to downregulate many of the same interferon-inducible genes. This suggests that there is a shared need between β-HPV and α-HPVs to target innate immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.